Clinical Trial Update: Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients [Phase 3]

View source ↗

Summary

This update describes a Phase 3 clinical trial evaluating systemic chemotherapy combined with recombinant human adenovirus type 5 and endostatin injections for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion
• Non-small Cell Lung Cancer

Drugs mentioned

• Endostatin (endostatin)
• Recombinant human adenovirus type 5 (Adenovirus type 5 vector)
• Systemic chemotherapy (unspecified regimen)

Snippet

Sponsor: Xinqiao Hospital of Chongqing | Conditions: Malignant Hydrothorax, Non Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN